Trial Profile
Bevacizumab (Avastin) therapy in combination with carboplatin and weekly paclitaxel for advanced non-squamous non-small cell lung cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 May 2017 Status changed from recruiting to completed.
- 19 Jan 2012 New trial record